Personalized Management of Heart Failure: From Biomarkers to Clinical Practice
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".
Deadline for manuscript submissions: 25 August 2026 | Viewed by 364
Special Issue Editor
Special Issue Information
Dear Colleagues,
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, representing one of the most pressing challenges in cardiovascular medicine. Despite significant advances in pharmacological and device-based therapies, the global burden of HF continues to rise, fueled by population aging, multimorbidity, and widening disparities in healthcare delivery. This Special Issue aims to address the rapidly evolving landscape of HF research and clinical practice, providing a platform for the generation of novel insights, critical discussions, and future perspectives.
This Special Issue aims to cover a wide range of contemporary topics in heart failure, including, but not limited to, the following:
- Advances in guideline-directed medical therapy (GDMT), including SGLT2 inhibitors, ARNIs, MRAs, and novel potassium binders.
- Precision medicine approaches and the role of genetics, biomarkers, and imaging in risk stratification.
- New perspectives on HF phenotypes, particularly HFpEF, HFmrEF, and their overlap with metabolic and renal syndromes.
- Digital health and artificial intelligence applications for remote monitoring, prognosis, and treatment optimization.
- Device therapy and interventional strategies, such as LV assist devices, percutaneous valve interventions, and remote hemodynamic monitoring.
- Global challenges in HF management, including implementation science, health policy, and equity of care.
The primary aim of this Special Issue is to stimulate the dissemination of cutting-edge research and promote interdisciplinary dialogue. Specifically, we seek to
- Bridge translational science with bedside application;
- Encourage the adoption of precision and personalized approaches to HF management;
- Highlight innovations in technology and pharmacology that are reshaping treatment paradigms;
- Foster international collaboration to address the unmet needs of HF patients worldwide.
For this Special Issue, original research, systematic reviews, clinical trials, and expert perspectives that explore the most relevant and timely topics in HF care are welcome to be submitted. Contributions will examine the effectiveness of novel therapeutics, the role of emerging biomarkers, strategies for optimizing care delivery, and the integration of AI-driven solutions into daily practice. By gathering insights from leaders across cardiology, nephrology, endocrinology, and digital health, this Special Issue aims to provide a multidisciplinary and future-oriented roadmap for improving outcomes in patients with HF.
Dr. Andre Rodrigues Durães
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart failure (HF)
- cardiac biomarkers
- guideline-directed medical therapy (GDMT)
- risk stratification
- HF phenotypes
- HF management
- digital health
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
